ARROWHEAD PHARMACEUTICALS, INC.ARWREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12.40% | 13.3M | — | 2024-01-23 |
| The Vanguard Group | 10.01% | 12.4M | ▲ +0.08pp | 2024-04-10 |
| Avoro Capital Advisors LLC | 7.20% | 8.9M | — | 2024-11-14 |
| STATE STREET CORPORATION | 5.10% | 6.4M | ▼ -1.25pp | 2024-10-16 |
Insider Transactions
Net 90d: −$2.33M · buys $0 / sells $2.33MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-23 | Hamilton James C | Chief Medical Officer | Sell (open market) | 10.0K | $75.00 | $750.0K |
| 2026-04-22 | Apel Daniel Joseph | Chief Financial Officer | Sell (open market) | 3.2K | $70.11 | $224.9K |
| 2026-04-22 | Apel Daniel Joseph | Chief Financial Officer | Sell (open market) | 1.2K | $70.45 | $81.5K |
| 2026-04-22 | Apel Daniel Joseph | Chief Financial Officer | Sell (open market) | 8.7K | $71.92 | $627.9K |
| 2026-03-05 | Hamilton James C | Chief Medical Officer | Sell (open market) | 10.0K | $64.19 | $641.9K |
1–5 of 5